Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10378) 10378
Publication (666) 666
Book Review (118) 118
Book / eBook (90) 90
Book Chapter (89) 89
Newsletter (13) 13
Dissertation (8) 8
Conference Proceeding (6) 6
Magazine Article (4) 4
Transcript (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8555) 8555
male (5263) 5263
female (4748) 4748
index medicus (4397) 4397
middle aged (4036) 4036
aged (4025) 4025
cancer (3566) 3566
oncology (2994) 2994
urinary bladder neoplasms - pathology (2507) 2507
carcinoma (2379) 2379
adult (2320) 2320
urology & nephrology (2299) 2299
bladder cancer (1912) 1912
tumors (1798) 1798
aged, 80 and over (1734) 1734
prognosis (1584) 1584
pathology (1472) 1472
carcinoma, transitional cell - pathology (1469) 1469
immunohistochemistry (1433) 1433
metastasis (1412) 1412
carcinoma, transitional cell - secondary (1383) 1383
chemotherapy (1221) 1221
animals (1220) 1220
expression (1067) 1067
neoplasm staging (1054) 1054
urinary bladder neoplasms - surgery (1048) 1048
care and treatment (1043) 1043
analysis (1014) 1014
retrospective studies (997) 997
carcinoma, transitional cell - surgery (975) 975
transitional-cell carcinoma (972) 972
research (968) 968
treatment outcome (959) 959
urothelial carcinoma (955) 955
surgery (915) 915
diagnosis (888) 888
bladder (887) 887
medicine & public health (848) 848
urinary bladder neoplasms - drug therapy (824) 824
urology (820) 820
survival (799) 799
neoplasm invasiveness (761) 761
risk factors (719) 719
cell line, tumor (703) 703
follow-up studies (697) 697
health aspects (696) 696
cystectomy (693) 693
carcinoma, transitional cell - drug therapy (667) 667
adenocarcinoma (653) 653
survival rate (645) 645
transitional-cell-carcinoma (639) 639
urinary bladder neoplasms - mortality (615) 615
development and progression (604) 604
apoptosis (594) 594
lymphatic metastasis (584) 584
proteins (581) 581
mice (573) 573
antineoplastic combined chemotherapy protocols - therapeutic use (572) 572
kidney neoplasms - pathology (567) 567
urinary-bladder (546) 546
gene expression (540) 540
urinary bladder neoplasms - metabolism (540) 540
diagnosis, differential (534) 534
radical cystectomy (532) 532
urinary bladder neoplasms - therapy (526) 526
cell biology (525) 525
transitional cell carcinoma (516) 516
bladder-cancer (510) 510
recurrence (510) 510
urinary bladder neoplasms - genetics (509) 509
disease-free survival (507) 507
carcinoma, transitional cell - mortality (500) 500
therapy (488) 488
disease progression (470) 470
cisplatin (453) 453
genetic aspects (449) 449
progression (449) 449
time factors (449) 449
combined modality therapy (418) 418
gene expression regulation, neoplastic (414) 414
medicine (413) 413
survival analysis (412) 412
neoplasm metastasis (411) 411
breast-cancer (407) 407
metastases (403) 403
carcinoma, transitional cell - diagnosis (402) 402
carcinoma, squamous cell - pathology (396) 396
squamous cell carcinoma (394) 394
carcinoma, transitional cell - therapy (388) 388
biomarkers, tumor - metabolism (385) 385
urinary bladder (382) 382
biopsy (375) 375
biomarkers, tumor - analysis (374) 374
article (372) 372
urinary bladder neoplasms - diagnosis (369) 369
research article (361) 361
patients (360) 360
carcinoma, transitional cell - metabolism (359) 359
radiotherapy (354) 354
immunotherapy (352) 352
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (67) 67
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (8) 8
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Gerstein Science - Circulation Desk (2) 2
Gerstein Science - Reference (2) 2
Humber River Regional Hospital - Finch Stacks (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
Online Resources - Online (2) 2
St Josephs Health Centre - Stacks (2) 2
St. Michael's Hospital - Stacks (2) 2
Credit Valley Hospital - Special Collections (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Markham Stouffville Hospital - Storage (1) 1
Mt Sinai Hospital - Pathology (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Hospital Department (1) 1
Trillium Health Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10164) 10164
Japanese (134) 134
Spanish (103) 103
French (62) 62
German (61) 61
Italian (23) 23
Chinese (10) 10
Portuguese (5) 5
Hebrew (4) 4
Polish (3) 3
Russian (3) 3
Arabic (2) 2
Turkish (2) 2
Dutch (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
by Alfred Witjes, J and Lebret, Thierry and Compérat, Eva M and Cowan, Nigel C and De Santis, Maria and Bruins, Harman Maxim and Hernández, Virginia and Espinós, Estefania Linares and Dunn, James and Rouanne, Mathieu and Neuzillet, Yann and Veskimäe, Erik and van der Heijden, Antoine G and Gakis, Georgios and Ribal, Maria J
European Urology, ISSN 0302-2838, 2016, Volume 71, Issue 3, pp. 462 - 475
Abstract Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate despite optimal treatment. The European Association of... 
Urology | Cystectomy | Treatment | Multimodality | EAU | Metastatic | Muscle invasive | Diagnosis | Bladder cancer | Follow-up | Guidelines | LYMPH-NODE DISSECTION | BACILLUS-CALMETTE-GUERIN | UROTHELIAL CARCINOMA | INTENSITY-MODULATED RADIOTHERAPY | PHASE-III TRIAL | URINARY-DIVERSION | TRANSITIONAL-CELL CARCINOMA | RADICAL CYSTECTOMY | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | RECURRENCE-FREE SURVIVAL | Neoplasm Invasiveness | Europe | Humans | Carcinoma, Transitional Cell - secondary | Cystoscopy | Carcinoma, Transitional Cell - therapy | Urinary Bladder - pathology | Radiotherapy | Neoplasm Metastasis | Societies, Medical | Carcinoma, Transitional Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Urinary Bladder Neoplasms - therapy | Urinary Bladder Neoplasms - pathology | BCG Vaccine - therapeutic use | Adjuvants, Immunologic - therapeutic use | Muscle, Smooth - pathology | Mortality | Metastasis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
by Joaquim Bellmunt and Christine Théodore and Tomasz Demkov and Boris Komyakov and Lisa Sengelov and Gedske Daugaard and Armelle Caty and Joan Carles and Agnieszka Jagiello-Gruszfeld and Oleg Karyakin and François-Michel Delgado and Patrick Hurteloup and Eric Winquist and Nassim Morsli and Yacine Salhi and Stéphane Culine and Hans von der Maase
Journal of Clinical Oncology, ISSN 0732-183X, 09/2009, Volume 27, Issue 27, pp. 4454 - 4461
Purpose Vinflunine (VFL) is a new microtubule inhibitor that has activity against transitional cell carcinoma of urothelial tract (TCCU). We conducted a... 
BLADDER-CANCER | WEEKLY PACLITAXEL | THERAPY | PROGNOSTIC-FACTORS | CISPLATIN | ONCOLOGY | 2ND-LINE TREATMENT | VINBLASTINE | GEMCITABINE | CHEMOTHERAPY | COOPERATIVE-ONCOLOGY-GROUP | Urologic Neoplasms - secondary | Humans | Middle Aged | Carcinoma, Transitional Cell - secondary | Palliative Care | Antineoplastic Agents - administration & dosage | Vinblastine - administration & dosage | Disease Progression | Urothelium - pathology | Urologic Neoplasms - drug therapy | Vinblastine - analogs & derivatives | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Platinum Compounds - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
by Sharma, Padmanee, Prof and Retz, Margitta, Prof and Siefker-Radtke, Arlene, MD and Baron, Ari, MD and Necchi, Andrea, MD and Bedke, Jens, Prof and Plimack, Elizabeth R, MD and Vaena, Daniel, MD and Grimm, Marc-Oliver, Prof and Bracarda, Sergio, MD and Arranz, José Ángel, MD and Pal, Sumanta, MD and Ohyama, Chikara, Prof and Saci, Abdel, PhD and Qu, Xiaotao, PhD and Lambert, Alexandre, PhD and Krishnan, Suba, MD and Azrilevich, Alex, PharmD and Galsky, Matthew D, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 312 - 322
Summary Background Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line chemotherapy. Responses to... 
Hematology, Oncology and Palliative Medicine | CISPLATIN | ONCOLOGY | TRANSITIONAL-CELL CARCINOMA | PD-1 BLOCKADE | RESISTANCE | SYSTEMIC THERAPY | CANCER | DOCETAXEL | GEMCITABINE | Prognosis | Follow-Up Studies | Humans | Middle Aged | Carcinoma, Transitional Cell - secondary | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Male | Survival Rate | Antineoplastic Agents - therapeutic use | Neoplasm Recurrence, Local - pathology | Urologic Neoplasms - pathology | Neoplasm Metastasis | Urologic Neoplasms - drug therapy | Carcinoma, Transitional Cell - drug therapy | Aged, 80 and over | Adult | Female | Aged | Neoplasm Staging | Platinum - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Chemotherapy | Carcinoma | Immunoglobulin G | Clinical trials | Product development | Metastasis | Antineoplastic agents | Cancer | Care and treatment | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
by Balar, Arjun V, Dr and Galsky, Matthew D, MD and Rosenberg, Jonathan E, MD and Powles, Thomas, MD and Petrylak, Daniel P, MD and Bellmunt, Joaquim, MD and Loriot, Yohann, MD and Necchi, Andrea, MD and Hoffman-Censits, Jean, MD and Perez-Gracia, Jose Luis, MD and Dawson, Nancy A, MD and van der Heijden, Michiel S, MD and Dreicer, Robert, MD and Srinivas, Sandy, MD and Retz, Margitta M, MD and Joseph, Richard W, MD and Drakaki, Alexandra, MD and Vaishampayan, Ulka N, MD and Sridhar, Srikala S, MD and Quinn, David I, MD and Durán, Ignacio, MD and Shaffer, David R, MD and Eigl, Bernhard J, MD and Grivas, Petros D, MD and Yu, Evan Y, MD and Li, Shi, PhD and Kadel, Edward E, BS and Boyd, Zachary, MSc and Bourgon, Richard, PhD and Hegde, Priti S, PhD and Mariathasan, Sanjeev, PhD and Thåström, AnnChristine, PhD and Abidoye, Oyewale O, MD and Fine, Gregg D, MD and Bajorin, Dean F, MD and IMvigor210 Study Grp and IMvigor210 Study Group
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 67 - 76
Summary Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short... 
Internal Medicine | BLADDER-CANCER | MEDICINE, GENERAL & INTERNAL | DOXORUBICIN | METHOTREXATE | VINBLASTINE | UNFIT | CLINICAL ACTIVITY | CELL CARCINOMA | CHEMOTHERAPY | GEMCITABINE | LONG-TERM-SURVIVAL | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Carcinoma, Transitional Cell - secondary | Antibodies, Monoclonal - therapeutic use | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Contraindications | Urologic Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Carcinoma, Transitional Cell - blood | Kaplan-Meier Estimate | Lymphatic Metastasis | Cisplatin | Biomarkers, Tumor - blood | Urologic Neoplasms - blood | B7-H1 Antigen - blood | Antibodies, Monoclonal - administration & dosage | Carcinoma, Transitional Cell - drug therapy | Aged | Infusions, Intravenous | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Carcinoma | Product development | Metastasis | Antineoplastic agents | Cancer | Clinical trials | Oncology | Ligands | Bladder cancer | Patients | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
by Joaquim Bellmunt and Toni K. Choueiri and Ronan Fougeray and Fabio A.B. Schutz and Yacine Salhi and Eric Winquist and Stéphane Culine and Hans von der Maase and David J. Vaughn and Jonathan E. Rosenberg
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 11, pp. 1850 - 1855
Purpose The present study sought to identify pretreatment [prognostic factors for overall survival (OS) in patients with metastatic transitional cell carcinoma... 
BLADDER-CANCER | PHASE-II TRIAL | GEMCITABINE PLUS CISPLATIN | VINFLUNINE | ONCOLOGY | DOXORUBICIN | METHOTREXATE | VINBLASTINE | TUMORS | CHEMOTHERAPY | LONG-TERM-SURVIVAL | Prognosis | Prospective Studies | Humans | Middle Aged | Risk Factors | Carcinoma, Transitional Cell - secondary | Hemoglobins - metabolism | Male | Survival Rate | Urinary Bladder Neoplasms - drug therapy | Clinical Trials, Phase III as Topic | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Treatment Failure | Carcinoma, Transitional Cell - drug therapy | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Neoplasm Staging | Organoplatinum Compounds - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma
by Wülfing, Christian and Machiels, Jean-Pascal H and Richel, Dirk J and Grimm, Marc-Oliver and Treiber, Uwe and de Groot, Marco R and Beuzeboc, Philippe and Parikh, Roma and Pétavy, Frank and El-Hariry, Iman A
Cancer, ISSN 0008-543X, 2009, Volume 115, Issue 13, pp. 2881 - 2890
BACKGROUND: The treatment of recurrent transitional cell carcinoma (TCC) remains an unmet clinical need. This study assessed lapatinib, a dual tyrosine kinase... 
lapatinib | HER‐2 | transitional cell carcinoma | bladder cancer | epidermal growth factor receptor | dual tyrosine kinase inhibitor | CLINICAL-TRIAL | PROGNOSTIC-FACTORS | RANDOMIZED-TRIAL | ADVANCED BLADDER-CANCER | II TRIAL | HER-2 | LONG-TERM-SURVIVAL | ONCOLOGY | SYSTEMIC CHEMOTHERAPY | ADVANCED UROTHELIAL CANCER | TRACT TUMORS | COOPERATIVE-ONCOLOGY-GROUP | Administration, Oral | Humans | Middle Aged | Carcinoma, Transitional Cell - secondary | Male | Treatment Outcome | Urinary Bladder Neoplasms - secondary | Urinary Bladder Neoplasms - drug therapy | Disease Progression | Platinum Compounds - therapeutic use | Carcinoma, Transitional Cell - pathology | Time Factors | Quinazolines - therapeutic use | Carcinoma, Transitional Cell - drug therapy | Quinazolines - adverse effects | Survival Analysis | Urinary Bladder Neoplasms - pathology | Adult | Female | Quinazolines - administration & dosage | Aged | Adenocarcinoma | Care and treatment | Research | Bladder cancer | Patient outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer
by Nguyen, Daniel P and Al Hussein Al Awamlh, Bashir and Wu, Xian and O’Malley, Padraic and Inoyatov, Igor M and Ayangbesan, Abimbola and Faltas, Bishoy M and Christos, Paul J and Scherr, Douglas S
European Urology, ISSN 0302-2838, 2015, Volume 68, Issue 3, pp. 399 - 405
Abstract Background Concerns remain whether robot-assisted radical cystectomy (RARC) compromises survival because of inadequate oncologic resection or... 
Urology | Recurrence | Local | Open radical cystectomy | Bladder cancer | Robot-assisted radical cystectomy | Distant | METASTASIS | EXTRACORPOREAL URINARY-DIVERSION | UROTHELIAL CARCINOMA | TUMOR | FOLLOW-UP | MODEL | PERIOPERATIVE OUTCOMES | TRANSITIONAL-CELL CARCINOMA | UROLOGY & NEPHROLOGY | COMPLICATIONS | EXPERIENCE | Adenocarcinoma - pathology | Lymph Nodes - pathology | Peritoneal Neoplasms - epidemiology | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Carcinoma, Transitional Cell - secondary | Carcinoma, Squamous Cell - surgery | Male | Female | Retrospective Studies | Peritoneal Neoplasms - secondary | Robotic Surgical Procedures | Proportional Hazards Models | Treatment Outcome | Laparoscopy | Urinary Bladder Neoplasms - surgery | Adenocarcinoma - secondary | Carcinoma, Transitional Cell - pathology | Urinary Bladder Neoplasms - parasitology | Carcinoma, Squamous Cell - secondary | Aged | Neoplasm Recurrence, Local - epidemiology | Carcinoma, Transitional Cell - surgery | Cystectomy - methods | Adenocarcinoma - surgery | Cohort Studies | Robotic surgery | Medical colleges | Robots
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
by Bellmunt, Joaquim and Mullane, S.A and Werner, L and Fay, A.P and Callea, M and Leow, J.J and Taplin, M.E and Choueiri, T.K and Hodi, F.S and Freeman, G.J and Signoretti, S
Annals of Oncology, ISSN 0923-7534, 04/2015, Volume 26, Issue 4, pp. 812 - 817
Background: Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) pathway negatively regulates T-cell-mediated responses. The prognostic impact of PD-L1... 
PD-L1 | Prognosis | Overall survival | Urothelial carcinoma | PD-1 | Immunotherapy | BACILLUS-CALMETTE-GUERIN | PROGNOSTIC-FACTORS | B7-H1 EXPRESSION | MECHANISMS | prognosis | CANCER | urothelial carcinoma | ONCOLOGY | INTEGRATIVE ANALYSIS | immunotherapy | overall survival | CD8(+) T-LYMPHOCYTES | BLADDER | IN-SITU | Carcinoma, Transitional Cell - mortality | Urologic Neoplasms - metabolism | Follow-Up Studies | Urologic Neoplasms - mortality | Humans | Carcinoma, Transitional Cell - secondary | Survival Rate | Carcinoma, Transitional Cell - metabolism | Immunoenzyme Techniques | Urologic Neoplasms - pathology | B7-H1 Antigen - metabolism | Animals | Lymphocytes, Tumor-Infiltrating - pathology | Biomarkers, Tumor - metabolism | Lymphocytes, Tumor-Infiltrating - metabolism | Mice
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Secondary transitional cell carcinoma and nitrogen mustard treatment
by DeLair, Sean M and de Vere White, Ralph W and Kurzrock, Eric A
Urology, ISSN 0090-4295, 2005, Volume 65, Issue 6, pp. 1226 - 1227
Transitional cell carcinoma (TCC) of the bladder in children is a rare occurrence. Cyclophosphamide is a known risk factor for the development of TCC. Other... 
UROLOGY & NEPHROLOGY | MALIGNANCIES | BLADDER | DISEASE | Humans | Mechlorethamine - adverse effects | Male | Lymphatic Irradiation | Mechlorethamine - therapeutic use | Urinary Bladder Neoplasms - chemically induced | Antineoplastic Agents, Alkylating - therapeutic use | Hodgkin Disease - radiotherapy | Neoplasms, Second Primary - chemically induced | Adolescent | Hodgkin Disease - drug therapy | Carcinoma, Transitional Cell - chemically induced | Antineoplastic Agents, Alkylating - adverse effects | Adenocarcinoma | Chemotherapy | Cyclophosphamide | Lymphomas | Drug therapy | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Surgical management for upper urinary tract transitional cell carcinoma (UUT‐TCC): a systematic review
by Rai, Bhavan Prasad and Shelley, Mike and Coles, Bernadette and Somani, Bhaskar and Nabi, Ghulam
BJU International, ISSN 1464-4096, 11/2012, Volume 110, Issue 10, pp. 1426 - 1435
What's known on the subject? and What does the study add? Upper urinary tract transitional cell carcinoma (UUT‐TCC) is an aggressive disease. The mainstay in... 
laparoscopy | ureterectomy | minimally invasive techniques | nephroureterectomy | transitional cell carcinoma | OPEN RADICAL NEPHROURETERECTOMY | ONCOLOGIC OUTCOMES | RENAL PELVIS | FOLLOW-UP | DISTAL URETER | ASSISTED LAPAROSCOPIC NEPHROURETERECTOMY | OPEN SURGERY | UROLOGY & NEPHROLOGY | RECURRENCE | CONSERVATIVE MANAGEMENT | BLADDER | Carcinoma, Transitional Cell - mortality | Urologic Surgical Procedures | Humans | Carcinoma, Transitional Cell - secondary | Neoplasm Recurrence, Local | Ureteral Neoplasms - pathology | Survival Rate | Laparoscopy | Kidney Neoplasms - mortality | Ureter - surgery | Disease-Free Survival | Kidney Neoplasms - surgery | Nephrectomy | Kidney Neoplasms - pathology | Carcinoma, Transitional Cell - surgery | Ureteral Neoplasms - mortality | Ureteral Neoplasms - surgery | Laparoscopic surgery | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phase II study of dual phosphoinositol‐3‐kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
by Seront, Emmanuel and Rottey, Sylvie and Filleul, Bertrand and Glorieux, Philippe and Goeminne, Jean‐Charles and Verschaeve, Vincent and Vandenbulcke, Jean‐Marie and Sautois, Brieuc and Boegner, Petra and Gillain, Aline and Maanen, Aline and Machiels, Jean‐Pascal
BJU International, ISSN 1464-4096, 09/2016, Volume 118, Issue 3, pp. 408 - 415
Objective To assess, in a multicentre phase II trial, the safety and efficacy of BEZ235, an oral pan‐class I phosphoinositol‐3‐kinase (PI3K) and mammalian... 
BEZ235 | mTOR inhibitor | transitional cell carcinoma | PI3K inhibitor | Transitional cell carcinoma | MTOR inhibitor | BLADDER-CANCER | OPEN-LABEL | GEMCITABINE | CHEMOTHERAPY | PACLITAXEL | TRIAL | PRETREATED PATIENTS | 2ND-LINE TREATMENT | UROLOGY & NEPHROLOGY | ADVANCED UROTHELIAL CANCER | SINGLE GROUP | Prospective Studies | Humans | Middle Aged | Carcinoma, Transitional Cell - secondary | Male | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | TOR Serine-Threonine Kinases - antagonists & inhibitors | Urologic Neoplasms - pathology | Urologic Neoplasms - drug therapy | Carcinoma, Transitional Cell - pathology | Carcinoma, Transitional Cell - drug therapy | Adult | Female | Aged | Quinolines - therapeutic use | Imidazoles - therapeutic use | Adenocarcinoma | Clinical trials | Care and treatment | Metastasis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights